Kyverna Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $7 Price Target
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Hold Rating, Maintains Target Price $7
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
J.P. Morgan Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $33
Kyverna Therapeutics Analyst Ratings
Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX), Smith Douglas Homes Corp. Class A (SDHC) and Kayne Anderson BDC, Inc. (KBDC)
H.C. Wainwright Initiates Kyverna Therapeutics(KYTX.US) With Hold Rating, Announces Target Price $7
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
Kyverna Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $33
HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $8 Price Target
Kyverna Therapeutics Analyst Ratings
HC Wainwright & Co. Initiates Coverage On Kyverna Therapeutics With Neutral Rating, Announces Price Target of $8
Kyverna Therapeutics Analyst Ratings
Buy Rating Affirmed on Kyverna Therapeutics Amid Anticipated Clinical Updates and Strong Financial Position
Kyverna Therapeutics Analyst Ratings
Morgan Stanley Initiates Coverage On Kyverna Therapeutics With Overweight Rating, Announces Price Target of $40